Histochemical detection of binding sites for human growth hormone using biotinylated ligand

Disulfide bonds determine growth hormone receptor folding, dimerisation and ligand binding

The growth hormone receptor contains seven cysteine residues in its extracellular domain. The six in the growth hormone binding domain form disulfide bonds, and help the receptor to gain its correct three-dimensional structure. In this study we replaced the cysteine for serine and alanine residues and investigated their role in growth hormone receptor folding, dimerisation and signal transduction. Folding and growth hormone binding capacity of the wild-type growth hormone receptor require less than two minutes for completion. Although less efficient, all mutant receptors arrive at the cell surface as pre-formed dimers. Disulfide bond C38-C48 is important for efficient maturation. The middle disulfide-bond, C83-C94, is important for ligand binding. Removing disulfide bond C108-C122 has little effect without affecting signalling. When two or all disulfide bonds are changed, ligand binding and activation are blocked. Dimerisation is delayed when all disulfide bonds are destroyed.

Bilayered clathrin coats on endosomal vacuoles are involved in protein sorting toward lysosomes

In many cells endosomal vacuoles show clathrin coats of which the function is unknown. Herein, we show that this coat is predominantly present on early endosomes and has a characteristic bilayered appearance in the electron microscope. By immunoelectron microscopy we show that the coat contains clathrin heavy as well as light chain, but lacks the adaptor complexes AP1, AP2, and AP3, by which it differs from clathrin coats on endocytic vesicles and recycling endosomes. The coat is insensitive to short incubations with brefeldin A, but disappears in the presence of the phosphatidylinositol 3-kinase inhibitor wortmannin. No association of endosomal coated areas with tracks of tubulin or actin was found. By quantitative immunoelectron microscopy, we found that the lysosomal-targeted receptors for growth hormone (GHR) and epidermal growth factor are concentrated in the coated membrane areas, whereas the recycling transferrin receptor is not. In addition, we found that the proteasomal inhibitor MG 132 induces a redistribution of a truncated GHR (GHR-369) toward recycling vesicles, which coincided with a redistribution of endosomal vacuole-associated GHR-369 to the noncoated areas of the limiting membrane. Together, these data suggest a role for the bilayered clathrin coat on vacuolar endosomes in targeting of proteins to lysosomes.

Novel non-isotopic method for the localization of receptors in tissue sections

We describe a novel fluorescent method for the detection of receptors for chimeric proteins in tissue sections. The technique was developed using a recombinant human insulin-like growth factor (IGF-1) chimera, bearing six additional histidine residues at the carboxy-terminal end (IGF-1-His). We demonstrated that dehydration of the tissue sections was detrimental for binding and that its prevention dramatically increased sensitivity. The specificity of IGF-1-His interaction was shown by gradual abolition of the fluorescent signal in the presence of increasing concentrations of IGF-1. Combining immunofluorescence with in situ ligand binding, we showed that IGF-1-His binding corresponded to the IGF-1 receptor (IGFR-1) distribution in human fetal kidney. Moreover, incubation of the tissue sections with an anti-IGFR-1 blocking antibody abolished IGF-1-His binding, demonstrating that the interaction was mediated by the IGFR-1. The method was also used to localize the IGFR-1 in E18 rat embryo sagittal sections. The IGF-1-His binding pattern was observed in brain, cartilage, lung, skin, heart, diaphragm, and tongue, and paralleled the previously reported IGFR-1 distribution. We believe that this new non-isotopic in situ ligand binding method will facilitate rapid and accurate localization of receptors in tissue sections.

The ubiquitin-dependent endocytosis motif is required for efficient incorporation of growth hormone receptor in clathrin-coated pits, but not clathrin-coated lattices

Endocytosis of the growth hormone receptor (GHR) requires an active ubiquitin-conjugation system. In addition, it depends on a 10 amino acid residues motif in the GHR-cytoplasmic tail, the ubiquitin dependent-endocytosis or UbE-motif. To gain insight into the role of ubiquitination in the early steps of endocytosis, we performed an ultrastructural analysis of GH-uptake in Chinese hamster cells expressing wild-type or mutant GHRs. In wild-type GHR cells, GH was found to be exclusively taken up via clathrin-coated pits. In early endosomes it was efficiently sorted from recycling transferrin and targeted to the degradative pathway. Mutation of all lysine residues of a truncated GHR (GHR-399K–) precludes ubiquitination of the receptor, but internalization of GHR-399K– still depends on an active ubiquitin system. We found that GHR-399K– incorporates GH into clathrin-coated vesicles with the same efficiency as wild-type GHR. By contrast, a mutation in the UbE-motif (GHR-F327A) largely abolished incorporation of GH into clathrin-coated vesicles. Notably, access of GH to clathrin-coated lattices was not affected in GHR-F327A cells. These data corroborate and extend previous data that the UbE-motif but not ubiquitination of the receptor itself recruits GHR into clathrin-coated vesicles. Moreover, they suggest that incorporation of GHR into clathrin-coated lattices is differentially regulated from incorporation into clathrin-coated pits.

Growth hormone receptor ubiquitination coincides with recruitment to clathrin-coated membrane domains

Endocytosis of the growth hormone receptor (GHR) depends on a functional ubiquitin conjugation system. A 10-amino acid residue motif within the GHR cytosolic tail (the ubiquitin-dependent endocytosis motif) is involved in both GHR ubiquitination and endocytosis. As shown previously, ubiquitination of the receptor itself is not required. In this paper ubiquitination of the GHR was used as a tool to address the question of at which stage the ubiquitin conjugation system acts in the process of GHR endocytosis. If potassium depletion was used to interfere with early stages of coated pit formation, both GHR endocytosis and ubiquitination were inhibited. Treatment of cells with methyl-beta-cyclodextrin inhibited endocytosis at the stage of coated vesicle formation. Growth hormone addition to methyl-beta-cyclodextrin-treated cells resulted in an accumulation of ubiquitinated GHR at the cell surface. Using immunoelectron microscopy, the GHR was localized in flattened clathrin-coated membranes. In addition, when clathrin-mediated endocytosis was inhibited in HeLa cells expressing a temperature-sensitive dynamin mutant, ubiquitinated GHR accumulated at the cell surface. Together, these data show that the GHR is ubiquitinated at the plasma membrane, before endocytosis occurs, and indicate that the resident time of the GHR at the cell surface is regulated by the ubiquitin conjugation system together with the endocytic machinery.

Localization of specific relaxin-binding cells in the ovary and testis of pigs

It is not known whether relaxin has physiological roles in the gonads in mammalian species. Limited evidence indicates that relaxin may act locally to regulate ovarian function in pigs. The possibility of a role for relaxin in testicular function in pigs has not been investigated. A major initial step toward the establishment of direct effects of relaxin on the ovary and/or testis is to demonstrate that relaxin binds with specificity to the gonads. Accordingly, the first objective of this study was to employ an immunohistochemical localization technique to determine whether relaxin-binding cells are present in the ovaries and/or testis of pigs. Once they were found to be present, the second objective was to determine whether relaxin-binding sites noticeably change either within the ovary at different stages of the estrous cycle and pregnancy, or within the testis at sexual maturity. Ovaries were collected from four stages of the estrous cycle (midfollicular, late follicular, early luteal, and midluteal) and three stages of the pregnancy (Day 40, Day 80, and Day 110). Two gilts were used for each of the stages of the estrous cycle and pregnancy. Testes were collected from a 5-mo-old immature boar and a 36-mo-old mature boar. Tissues were cut into cubes (3-4 cm3), frozen in liquid nitrogen, and cryosectioned (8 microm). Specific cell types that bind relaxin were identified by sequential application of a biotinylated relaxin probe, antibiotin immunoglobulin G conjugated to 1 nm colloidal gold, and silver for signal amplification. In the ovary, specific relaxin-binding sites were localized in both the theca and granulosa cells of developing follicles, luteal cells, and blood vessels. In the testis, specific relaxin-binding sites were localized in the Leydig cells. There were no apparent differences in relaxin-binding distribution within the ovary at different stages of the estrous cycle and pregnancy in gilts, or within the testis at sexual maturity in boars. We conclude that the specific relaxin-binding cells within the ovary and testis of the pig may contain relaxin receptors. Therefore, relaxin may have effects in the ovary and testis of pigs.

Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA

The urokinase-type plasminogen activator (uPA) is a serine protease that plays a crucial role in blood coagulation and in tumor invasion and metastasis. uPA is a relatively large polypeptide and binds the uPA receptor (uPAR) with high affinity and specificity. Therefore, it was a good candidate for direct labeling with a fluorochrome for detection of the uPAR. We have produced a fluorescein (FITC)-labeled human uPA using a conjugation procedure that did not significantly alter its binding characteristics to the uPAR. Thirty nM FITC-uPA efficiently stains 2 x 10(5) uPAR-transfected mouse cells in suspension, as determined by flow cytometric analysis. One microgram of FITC-uPA efficiently stains 2 x 10(5) uPAR transfectants grown on slides and analyzed by fluorescence optical microscopy. Human cell lines expressing the endogenous uPAR were stained with similar efficiency. Fixation in paraformaldehyde only slightly reduced the efficiency of staining of both transfectants and cell lines. These characteristics allow the use of FITC-uPA in both static and dynamic morphological studies of uPAR-expressing cells.